Thomas Cummin

807 total citations
6 papers, 46 citations indexed

About

Thomas Cummin is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Thomas Cummin has authored 6 papers receiving a total of 46 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pathology and Forensic Medicine, 3 papers in Molecular Biology and 3 papers in Oncology. Recurrent topics in Thomas Cummin's work include Lymphoma Diagnosis and Treatment (4 papers), CAR-T cell therapy research (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Thomas Cummin is often cited by papers focused on Lymphoma Diagnosis and Treatment (4 papers), CAR-T cell therapy research (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Thomas Cummin collaborates with scholars based in United Kingdom. Thomas Cummin's co-authors include Peter Johnson, Yan Ma, Kerry L. Cox, Ben Powell, Matthew Carter, Graham Packham, Mark S. Cragg, Sharon Barrans, Josh Caddy and Andrew Davies and has published in prestigious journals such as Blood, Laboratory Investigation and Blood Advances.

In The Last Decade

Thomas Cummin

5 papers receiving 46 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Cummin United Kingdom	4	32	18	16	13	9	6	46
Susanne Kratzat Germany	3	38 1.2×	27 1.5×	6 0.4×	10 0.8×	5 0.6×	3	50
Sonia Fox United Kingdom	4	22 0.7×	11 0.6×	20 1.3×	13 1.0×	20 2.2×	11	41
Katya Ahr United States	3	18 0.6×	20 1.1×	29 1.8×	6 0.5×	16 1.8×	4	45
Phillip Michaels United States	4	10 0.3×	10 0.6×	28 1.8×	19 1.5×	13 1.4×	12	63
Shaneice Mitchell United States	4	22 0.7×	8 0.4×	12 0.8×	27 2.1×	17 1.9×	8	47
Letitia Lensun United States	3	33 1.0×	6 0.3×	10 0.6×	4 0.3×	10 1.1×	3	42
Matteo Costacurta Australia	4	49 1.5×	18 1.0×	8 0.5×	30 2.3×	6 0.7×	4	59
Elisabetta Cretella Italy	4	16 0.5×	20 1.1×	20 1.3×	7 0.5×	5 0.6×	6	46
Martina Finetti United Kingdom	3	55 1.7×	13 0.7×	32 2.0×	4 0.3×	6 0.7×	8	70
Neus Ruiz‐Xivillé Spain	6	10 0.3×	8 0.4×	16 1.0×	15 1.2×	15 1.7×	8	34

Countries citing papers authored by Thomas Cummin

Since Specialization

Citations

This map shows the geographic impact of Thomas Cummin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Cummin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Cummin more than expected).

Fields of papers citing papers by Thomas Cummin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Cummin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Cummin. The network helps show where Thomas Cummin may publish in the future.

Co-authorship network of co-authors of Thomas Cummin

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Cummin. A scholar is included among the top collaborators of Thomas Cummin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Cummin. Thomas Cummin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Cummin, Thomas, Kerry L. Cox, Graham Packham, et al.. (2020). BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression. Blood Advances. 4(14). 3316–3328. 28 indexed citations

2.

Davies, Andrew, Josh Caddy, Louise Stanton, et al.. (2020). Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study. Blood. 136(Supplement 1). 38–39. 3 indexed citations

3.

Davies, Andrew, Thomas Cummin, Louise Stanton, et al.. (2019). ARGO: A RANDOMISED PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH‐DOSE THERAPY. Hematological Oncology. 37(S2). 555–556.

4.

Cummin, Thomas, Tom Maishman, Anna Schuh, et al.. (2019). ACCEPT: A PHASE IB/II COMBINATION OF ACALABRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISOLONE (R‐CHOP) FOR PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). Hematological Oncology. 37(S2). 71–72. 4 indexed citations

5.

Cucco, Francesco, Alexandra Clipson, Hannah Kennedy, et al.. (2018). Mutation screening using formalin-fixed paraffin-embedded tissues: a stratified approach according to DNA quality. Laboratory Investigation. 98(8). 1084–1092. 6 indexed citations

6.

Cummin, Thomas & Peter Johnson. (2016). Lymphoma: turning biology into cures. Clinical Medicine. 16(6). s125–s129. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact